{"id":998195,"date":"2026-08-26T08:35:55","date_gmt":"2026-08-26T12:35:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/"},"modified":"2026-08-26T08:35:55","modified_gmt":"2026-08-26T12:35:55","slug":"20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/","title":{"rendered":"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>CEO Jonathan Cohen to Detail the Company\u2019s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open<\/em>\n      <\/p>\n<p align=\"justify\">GAITHERSBURG, Md., Aug.  26, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TvUWssidrOesKL9kh-3URyMGhqrj7MloGr4DdvGfIXGxtWWoH70CSSxYblpQ5BQdKSyCu95FErrt6l231-5WaPHn--X3ymvFX1t992YWqnM=\" rel=\"nofollow\" target=\"_blank\">20\/20 BioLabs, Inc.<\/a> (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, September 2, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the Company\u2019s second quarter 2026 results, which included the highest OneTest\u2122 revenue in the Company\u2019s history, as well as his presentation at the 18th Annual Next Generation Dx Summit and how the science he presented there connects to the Company\u2019s commercial, regulatory, and reimbursement strategy.<\/p>\n<p align=\"justify\">To access the webinar, please use the following information:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Date<\/strong>:<\/td>\n<td style=\"vertical-align: top\">Wednesday, September 2, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Time<\/strong>:<\/td>\n<td style=\"vertical-align: top\">12:00 p.m. Eastern time (9:00 a.m. Pacific time)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Webcast<\/strong>:<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/us02web.zoom.us\/webinar\/register\/WN_AhJ09s-wTC-VA1O2AnEKsA\" rel=\"nofollow\" target=\"_blank\">Please click here to register.<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">During the webinar, management expects to address the following topics:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">A review of the Company\u2019s second quarter 2026 results, including record OneTest\u2122 revenue of $0.7 million, an increase of 47.1% year-over-year. Management believes this was the strongest quarterly performance since commercial launch of multi-cancer early detection (\u201cMCED\u201d) testing;<\/li>\n<li style=\"text-align:justify\">The operating leverage the Company is beginning to demonstrate in its laboratory model, with gross profit increasing 86.6% and gross margin expanding to 41.7% from 30.5%, and how management expects incremental testing volume to be absorbed across a largely fixed laboratory cost base;<\/li>\n<li style=\"text-align:justify\">Key takeaways from Mr. Cohen\u2019s presentation at the 18th Annual Next Generation Dx Summit in Washington, D.C., \u201cAligning MCED with MAHA: Combining Protein Tumor and Inflammatory Biomarkers for Both Early Detection and Prevention of Cancers through Anti-Inflammatory Lifestyle Enhancements,\u201d and what he heard from the clinical, regulatory, and commercial leaders in attendance;<\/li>\n<li style=\"text-align:justify\">The evolution of the OneTest\u2122 platform, from a first-generation MCED blood test built on protein tumor biomarkers, to a second generation that adds inflammatory biomarkers, to a planned third-generation test designed for quarterly monitoring of both biomarker classes using at-home, upper-arm capillary blood collection devices;<\/li>\n<li style=\"text-align:justify\">Continued momentum in state-funded firefighter cancer screening, including Vermont\u2019s 12-month statewide initiative to screen up to 4,500 firefighters and the $520,000 awarded to Maryland fire departments, the revenue the Company expects these programs to generate through the end of 2026, and its expected path to having tested more than 35,000 firefighters by year-end;<\/li>\n<li style=\"text-align:justify\">How that growing body of real-world evidence is intended to support the Company\u2019s regulatory and reimbursement strategy, including the statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028, and the Company\u2019s serial biomarker tracking methodology, which follows biomarker trajectories over time rather than relying on single-point testing;<\/li>\n<li style=\"text-align:justify\">Commercial expansion across occupational health, military, intelligence community, physician practice, and retail channels, including the 29 new accounts added during the second quarter; and<\/li>\n<li style=\"text-align:justify\">A live question-and-answer session with management.<\/li>\n<\/ul>\n<p align=\"justify\">\u201cThe second quarter was the strongest quarterly performance since commercial launch for multi-cancer early detection testing, and the audience I addressed at the Next Generation Dx Summit is exactly the group that shapes how quickly tests like ours reach patients,\u201d said Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs. \u201cOn September 2, I want to connect those two threads for investors: the science of pairing protein tumor markers with inflammatory markers for both detection and prevention, and the commercial and reimbursement pathway that record OneTest\u2122 volume is helping us build.\u201d<\/p>\n<p align=\"justify\">The September 2 webinar is part of the Company\u2019s monthly investor webinar series, held on the first Wednesday of each month at 12:00 p.m. Eastern time. Investors and other interested parties are encouraged to submit questions in advance to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KbfgaTxtr5pZlVkTAdA0X-vAQzrZo0XpZJWSn-s4a2EaFcgNBfnz9p7WjawoiBcHevbrLU4wE0GDOA_8ObHy5A==\" rel=\"nofollow\" target=\"_blank\">AIDX@mzgroup.us<\/a>. A replay will be made available through the Company\u2019s investor relations website following the event.<\/p>\n<p align=\"justify\">As part of its commitment to expanding access to early cancer detection, 20\/20 BioLabs will provide webinar attendees with a promotional discount code for OneTest\u2122 at the conclusion of the event. The offer will be available to all attendees, regardless of shareholder status.<\/p>\n<p align=\"justify\">Additional detail on the Company\u2019s second quarter 2026 results is available in the earnings release issued on August 17, 2026, and in the Company\u2019s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission. The webinar is not expected to include the disclosure of any material non-public information.<\/p>\n<p align=\"justify\">\n        <strong>About 20\/20 BioLabs<\/strong>\n      <\/p>\n<p align=\"justify\">20\/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest\u2122 for Cancer is a multi-cancer early detection blood test and OneTest\u2122 for Longevity measures inflammatory biomarkers and is commercially available. OneTest\u2019s tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company\u2019s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.<\/p>\n<p>For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FtNo8PuuelC_mjx5RfSH-NvArxUruCuFHur6d2HhdlnMrC58gOLcn6HGXCBVp8PaGjn-9neshblkzZIY2ITUuLDxq3cxLf3P_Ui2eO4zEGo=\" rel=\"nofollow\" target=\"_blank\">https:\/\/2020biolabs.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company\u2019s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, regulatory strategy, reimbursement strategy, growth strategy, and financial needs. Forward-looking statements can be identified by words such as \u201cmay,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable expressions. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company\u2019s filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), which are available on the SEC\u2019s website at www.sec.gov, including the Company\u2019s most recent Annual Report on Form 10-K, as well as in its other reports filed or furnished from time to time with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law. Although the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee future results, and investors are cautioned that actual outcomes may differ materially from those anticipated.<\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Chris Tyson<br \/>MZ Group<br \/>Direct: 949-491-8235<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KbfgaTxtr5pZlVkTAdA0XwmOE51zfg5kEovvz9rAcamOYU2KhAmhqbPsjrdhdNs3Z6XAxgBHTxdDSd7qJCqdpUm8Kpc1FnrPsq3TwGTf_jE=\" rel=\"nofollow\" target=\"_blank\">AIDX@mzgroup.us<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODdjMGQ3N2EtOGFjZS00NWUwLTgxYjMtOTM0ODJjOGRjMjFmLTEzMjA0MzgtMjAyNi0wOC0yNi1lbg==\/tiny\/20-20-Biolabs-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CEO Jonathan Cohen to Detail the Company\u2019s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 26, 2026 (GLOBE NEWSWIRE) &#8212; 20\/20 BioLabs, Inc. (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, September 2, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the Company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-998195","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CEO Jonathan Cohen to Detail the Company\u2019s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 26, 2026 (GLOBE NEWSWIRE) &#8212; 20\/20 BioLabs, Inc. (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, September 2, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the Company\u2019s &hellip; Continue reading &quot;20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T12:35:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"20\\\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity\",\"datePublished\":\"2026-08-26T12:35:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/\"},\"wordCount\":1157,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/\",\"name\":\"20\\\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=\",\"datePublished\":\"2026-08-26T12:35:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"20\\\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/","og_locale":"en_US","og_type":"article","og_title":"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity - Market Newsdesk","og_description":"CEO Jonathan Cohen to Detail the Company\u2019s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 26, 2026 (GLOBE NEWSWIRE) &#8212; 20\/20 BioLabs, Inc. (Nasdaq: AIDX) (\u201c20\/20 BioLabs\u201d or the \u201cCompany\u201d), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, September 2, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer of 20\/20 BioLabs, will discuss the Company\u2019s &hellip; Continue reading \"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-26T12:35:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity","datePublished":"2026-08-26T12:35:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/"},"wordCount":1157,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/","name":"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=","datePublished":"2026-08-26T12:35:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI5MiM3ODAzODEwIzIzMDg4ODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/20-20-biolabs-to-host-investor-webinar-on-september-2-2026-to-discuss-onetest-revenue-and-expanding-commercial-opportunity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"20\/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest\u2122 Revenue and Expanding Commercial Opportunity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=998195"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=998195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=998195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=998195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}